ReportWire

Tag: Medical

  • Louisiana State Employees Retirement System Sells 100 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

    Louisiana State Employees Retirement System Sells 100 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

    [ad_1]

    Louisiana State Employees Retirement System decreased its position in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 3.0% during the 2nd quarter, Holdings Channel reports. The firm owned 3,200 shares of the medical research company’s stock after selling 100 shares during the quarter. Louisiana State Employees Retirement System’s holdings in Charles River Laboratories International were worth $673,000 at the end of the most recent reporting period.

    Several other large investors have also made changes to their positions in CRL. Moneta Group Investment Advisors LLC bought a new stake in shares of Charles River Laboratories International in the 4th quarter worth about $298,877,000. Price T Rowe Associates Inc. MD grew its holdings in shares of Charles River Laboratories International by 35.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,506,293 shares of the medical research company’s stock worth $505,821,000 after purchasing an additional 653,790 shares during the last quarter. Norges Bank bought a new stake in shares of Charles River Laboratories International in the 4th quarter worth about $97,675,000. Southpoint Capital Advisors LP bought a new stake in shares of Charles River Laboratories International in the 1st quarter worth about $80,728,000. Finally, Clearbridge Investments LLC grew its holdings in shares of Charles River Laboratories International by 28.2% in the 1st quarter. Clearbridge Investments LLC now owns 1,368,943 shares of the medical research company’s stock worth $388,739,000 after purchasing an additional 301,159 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

    Charles River Laboratories International Stock Performance

    Charles River Laboratories International stock opened at $195.62 on Wednesday. The company has a current ratio of 1.49, a quick ratio of 1.21 and a debt-to-equity ratio of 0.82. Charles River Laboratories International, Inc. has a 1 year low of $181.22 and a 1 year high of $262.00. The company has a market cap of $10.03 billion, a PE ratio of 20.74, a PEG ratio of 1.96 and a beta of 1.33. The company’s 50-day moving average is $202.47 and its two-hundred day moving average is $201.57.

    Charles River Laboratories International (NYSE:CRL – Get Free Report) last released its earnings results on Wednesday, August 9th. The medical research company reported $2.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.63 by $0.06. The company had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.05 billion. Charles River Laboratories International had a net margin of 11.58% and a return on equity of 18.99%. The company’s revenue was up 8.9% compared to the same quarter last year. During the same period in the prior year, the company posted $2.77 EPS. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 10.49 earnings per share for the current year.

    Wall Street Analysts Forecast Growth

    CRL has been the topic of several analyst reports. Bank of America lowered their target price on shares of Charles River Laboratories International from $245.00 to $230.00 in a report on Friday, September 22nd. StockNews.com began coverage on shares of Charles River Laboratories International in a report on Thursday, October 5th. They set a “hold” rating on the stock. Guggenheim decreased their price objective on shares of Charles River Laboratories International from $255.00 to $225.00 and set a “buy” rating on the stock in a report on Friday, September 22nd. JPMorgan Chase & Co. increased their price objective on shares of Charles River Laboratories International from $225.00 to $250.00 and gave the stock an “overweight” rating in a report on Thursday, August 10th. Finally, TD Cowen decreased their price objective on shares of Charles River Laboratories International from $212.00 to $209.00 and set a “market perform” rating on the stock in a report on Monday, September 25th. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $237.09.

    Get Our Latest Analysis on Charles River Laboratories International

    Insider Activity at Charles River Laboratories International

    In related news, EVP Joseph W. Laplume sold 700 shares of the stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $216.52, for a total value of $151,564.00. Following the sale, the executive vice president now directly owns 24,983 shares in the company, valued at approximately $5,409,319.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Joseph W. Laplume sold 700 shares of the stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $216.52, for a total value of $151,564.00. Following the sale, the executive vice president now directly owns 24,983 shares in the company, valued at approximately $5,409,319.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP William D. Barbo sold 5,763 shares of the stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $217.24, for a total transaction of $1,251,954.12. Following the completion of the sale, the vice president now owns 3,592 shares in the company, valued at $780,326.08. The disclosure for this sale can be found here. Insiders have sold 7,934 shares of company stock worth $1,722,048 in the last ninety days. Company insiders own 1.30% of the company’s stock.

    Charles River Laboratories International Company Profile

    (Free Report)

    Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

    Recommended Stories

    Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL – Free Report).

    Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

    Receive News & Ratings for Charles River Laboratories International Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Charles River Laboratories International and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Robeco Institutional Asset Management B.V. Sells 7,276 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

    Robeco Institutional Asset Management B.V. Sells 7,276 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

    [ad_1]

    Robeco Institutional Asset Management B.V. reduced its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 4.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 155,163 shares of the company’s stock after selling 7,276 shares during the quarter. Robeco Institutional Asset Management B.V. owned 0.16% of Neurocrine Biosciences worth $14,632,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

    Several other institutional investors also recently modified their holdings of the business. BlackRock Inc. raised its stake in Neurocrine Biosciences by 6.6% during the 1st quarter. BlackRock Inc. now owns 13,466,650 shares of the company’s stock valued at $1,363,094,000 after buying an additional 838,997 shares during the last quarter. State Street Corp grew its holdings in shares of Neurocrine Biosciences by 1.9% in the first quarter. State Street Corp now owns 3,799,915 shares of the company’s stock worth $384,627,000 after acquiring an additional 69,729 shares during the period. Renaissance Technologies LLC lifted its holdings in Neurocrine Biosciences by 20.7% in the first quarter. Renaissance Technologies LLC now owns 1,947,064 shares of the company’s stock valued at $197,082,000 after acquiring an additional 333,400 shares during the period. Armistice Capital LLC boosted its position in Neurocrine Biosciences by 76.9% in the first quarter. Armistice Capital LLC now owns 1,592,000 shares of the company’s stock worth $161,142,000 after purchasing an additional 692,000 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Neurocrine Biosciences by 3.4% during the 1st quarter. Geode Capital Management LLC now owns 1,435,737 shares of the company’s stock valued at $145,127,000 after purchasing an additional 47,042 shares during the period. 93.54% of the stock is owned by hedge funds and other institutional investors.

    Neurocrine Biosciences Stock Down 1.2 %

    Neurocrine Biosciences stock opened at $113.93 on Monday. Neurocrine Biosciences, Inc. has a twelve month low of $89.04 and a twelve month high of $129.29. The company’s 50-day moving average price is $109.08 and its 200-day moving average price is $101.67. The company has a market cap of $11.13 billion, a PE ratio of 65.86, a price-to-earnings-growth ratio of 1.13 and a beta of 0.44.

    Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last announced its earnings results on Tuesday, August 1st. The company reported $0.95 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.18. Neurocrine Biosciences had a return on equity of 10.39% and a net margin of 10.54%. The firm had revenue of $452.70 million during the quarter, compared to analysts’ expectations of $448.29 million. As a group, sell-side analysts expect that Neurocrine Biosciences, Inc. will post 2.2 earnings per share for the current fiscal year.

    Insiders Place Their Bets

    In other news, insider Jude Onyia sold 3,198 shares of the firm’s stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $107.37, for a total value of $343,369.26. Following the completion of the sale, the insider now owns 9,638 shares in the company, valued at approximately $1,034,832.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Jude Onyia sold 3,198 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $107.37, for a total transaction of $343,369.26. Following the completion of the sale, the insider now directly owns 9,638 shares of the company’s stock, valued at approximately $1,034,832.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Matt Abernethy sold 2,132 shares of Neurocrine Biosciences stock in a transaction on Monday, August 21st. The stock was sold at an average price of $107.39, for a total value of $228,955.48. Following the sale, the chief financial officer now owns 27,131 shares of the company’s stock, valued at $2,913,598.09. The disclosure for this sale can be found here. Insiders sold 31,083 shares of company stock valued at $3,400,811 over the last three months. 4.40% of the stock is owned by company insiders.

    Analyst Ratings Changes

    Several brokerages have recently weighed in on NBIX. JPMorgan Chase & Co. increased their price objective on shares of Neurocrine Biosciences from $133.00 to $134.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 13th. Cantor Fitzgerald reissued an “overweight” rating and set a $136.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday, September 13th. Canaccord Genuity Group upped their price objective on Neurocrine Biosciences from $132.00 to $144.00 and gave the stock a “buy” rating in a research note on Wednesday, September 13th. TheStreet raised Neurocrine Biosciences from a “c” rating to a “b-” rating in a report on Tuesday, August 1st. Finally, Barclays raised their price objective on Neurocrine Biosciences from $125.00 to $134.00 in a research note on Thursday, September 21st. Five investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $130.79.

    Read Our Latest Analysis on NBIX

    About Neurocrine Biosciences

    (Free Report)

    Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company’s portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.

    Recommended Stories

    Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report).

    Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

    Receive News & Ratings for Neurocrine Biosciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Neurocrine Biosciences and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Monument Capital Management Acquires New Position in Johnson & Johnson (NYSE:JNJ)

    Monument Capital Management Acquires New Position in Johnson & Johnson (NYSE:JNJ)

    [ad_1]

    Monument Capital Management acquired a new stake in Johnson & Johnson (NYSE:JNJ – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,332 shares of the company’s stock, valued at approximately $386,000.

    Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Atlantic Private Wealth LLC acquired a new position in shares of Johnson & Johnson during the first quarter worth approximately $32,000. Dark Forest Capital Management LP lifted its position in Johnson & Johnson by 1,044.4% in the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after purchasing an additional 188 shares during the period. Ruedi Wealth Management Inc. acquired a new stake in Johnson & Johnson in the fourth quarter worth approximately $42,000. Kepos Capital LP acquired a new stake in Johnson & Johnson in the fourth quarter worth approximately $45,000. Finally, 25 LLC acquired a new stake in Johnson & Johnson in the first quarter worth approximately $55,000. 68.40% of the stock is owned by institutional investors.

    Johnson & Johnson Stock Performance

    NYSE:JNJ opened at $155.75 on Monday. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $404.79 billion, a P/E ratio of 31.53, a price-to-earnings-growth ratio of 3.15 and a beta of 0.55. The firm has a 50 day moving average of $165.97 and a 200-day moving average of $162.29. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $181.04.

    Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. The business had revenue of $25.53 billion during the quarter, compared to analyst estimates of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. Johnson & Johnson’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.59 earnings per share. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

    Johnson & Johnson Dividend Announcement

    The firm also recently announced a quarterly dividend, which was paid on Thursday, September 7th. Shareholders of record on Monday, August 28th were issued a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a yield of 3.06%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s dividend payout ratio is presently 96.36%.

    Analyst Upgrades and Downgrades

    Several research firms have issued reports on JNJ. TheStreet raised Johnson & Johnson from a “c+” rating to a “b+” rating in a report on Monday, August 21st. Credit Suisse Group boosted their target price on shares of Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, July 21st. JPMorgan Chase & Co. upped their price target on shares of Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a research note on Friday, July 21st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Monday, September 18th. Finally, HSBC assumed coverage on shares of Johnson & Johnson in a report on Wednesday, September 6th. They issued a “hold” rating and a $175.00 price objective for the company. Nine investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Hold” and an average price target of $170.65.

    Get Our Latest Stock Report on JNJ

    Insiders Place Their Bets

    In other news, insider William Hait sold 14,698 shares of the business’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the transaction, the insider now owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, insider William Hait sold 14,698 shares of the business’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the sale, the insider now directly owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the sale, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The disclosure for this sale can be found here. Company insiders own 0.20% of the company’s stock.

    Johnson & Johnson Profile

    (Free Report)

    Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

    Further Reading

    Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

    Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

    Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Rising health costs could make it harder for the Fed to get inflation down to 2%

    Rising health costs could make it harder for the Fed to get inflation down to 2%

    [ad_1]

    The rate of U.S. inflation has slowed considerably from a 40-year peak of 9.1% in mid-2022 and it’s gotten an assist from a surprising source: falling medical costs.

    But that’s about to end — to a large degree because of the complex way the federal government tries to figure the rise of medical costs. And a re-acceleration in health-care costs could complicate the Federal Reserve’s job to get inflation back down to pre-pandemic levels of 2% or less.

    “Unfortunately, the bill is about to become due” said economist Omair Sharif, founder of research firm Inflation Insights. “It’s going to be more of a headache for the Fed.”

    Ever-rising medical costs

    Rising medical costs have long been one of the biggest sources of inflation, even in times when overall U.S. prices were growing slowly. Medical costs rose an average of 3% a year in the decade prior to the pandemic and even faster in the early 2000s.

    Expensive health care was one the chief drivers of former President Barack Obama’s attempt to create a national health care system more than a decade ago.

    Yet medical costs began to decelerate sharply about one year ago, and in July, they turned negative for the first time since Word War Two. At least according to the complicated formula by which the federal government measures these expenses.

    The consumer price index, the nation’s main inflation gauge, showed that the annual cost of medical care fell by 1% in the 12 months ended in August. Less than a year before, they were rising at a 6% pace.

    Now, no one really believes medical costs are falling. Historically prices rise every year. And just this week The Wall Street Journal reported that health insurance could post the biggest price increase in 2024 in more than a decade.

    So what’s going on?

    Well, the government’s method for determining health-care prices has always been flawed — and the pandemic only made the problem worse. Far worse.

    The cost of health care is almost impossible to measure accurately, economists say. It’s easy to determine the price of gas or a loaf of bread. Not so the cost of a trip to the emergency room or even a routine visit to one’s doctor.

    Prices charged by doctors and hospitals are opaque, for one thing, and differ sharply even in the same city. It’s also difficult to gauge patient outcomes. And payments for services rendered are split by businesses, consumers and government (Medicare and Medicaid).

    “How do you measure outcomes? Is it an hour in the hospital? Is it making a patient healthy,” said Stephen Stanley, chief economist at Santander Capital Markets. “How do you measure any of this?”

    Then came the pandemic

    The government had to come up with a workaround, and it did.

    Basically the CPI formula subtracts the cost of benefits paid by health insurers on behalf of customers from the amount of premiums they pay. Whatever profits are leftover each year — known as retained earnings — are used to determine how much health-care prices are rising.

    The formula works all right in normal times, but the coronavirus threw a huge curve ball.

    Americans stopped going to the hospital or doctor’s office during Covid for fear of catching the virus. Health insurers paid out far less in benefits and profits soared.

    As the pandemic faded and Americans went back to their doctors, health insurers had to pay much more in benefits and profits sank.

    The result: Health-care costs as measured by the CPI have shown unprecedented ups and downs since the pandemic, especially since the government only updates its math for the medical index once a year in October.

    Just how big are these swings?

    The annual cost of health insurance in the CPI soared by a reported 28% as of September 2022, only to sink by 33% as of August.

    Now here comes another swing. Health insurance costs are set to rise sharply starting in October after the government’s next update to its CPI formula.

    That could spell trouble for the Fed.

    The ‘core’ of the problem

    The goal of the central bank is to get inflation back down to 2%, especially the core rate that strips out volatile food and energy costs.

    The core rate of the CPI already slowed considerably in the past year, decelerating to a yearly pace of 4.3% last month from a four-decade peak of 6.6% in mid-2022.

    The supposed plunge in health-insurance costs helped pave the way.

    At Inflation Insights, Shariff estimates the core CPI would have slowed to only 5.1% — not 4.3% — if health-care costs had risen in the past 11 months as fast as they were rising in September 2022.

    What about in the year ahead, when health insurance costs accelerate in the CPI? Medical care is the third biggest category in the index after housing and groceries.

    Economists are split how much it could impede the Fed in its effort to get inflation down to 2%.

    Shariff, for his part, thinks rising medical costs could add three-tenths or more to core CPI by next spring.

    “It’s going to start adding back to core inflation,” he said.

    At Santander Capital Markets, Stanley was one of the first Wall Street
    DJIA
    economists to warn about high inflation a few years ago. He is less sure rising medical costs will undermine the Fed’s inflation fight. “It is a really important category, but it’s probably not getting worked up about.”

    Other economists believe inflation is likely to continue to slow toward 2% largely because of easing price pressures in many other major categories such as food and especially shelter.

    Rents have come off a boil, for example, and housing prices aren’t rising rapidly anymore. Shelter accounts for more than one-third of the CPI versus a little over 8% for medical costs.

    “CPI only barely starting to show the slowdown in shelter costs,” said Simona Mocuta, chief economist at State Street Global Advisors.

    An alternative approach

    Senior economist Aichi Amemiya at Nomura said it’s better to focus on a separate measure of health-care costs preferred by the Fed that shows more stability.

    The health-service gauge found in the so-called PCE index shows that costs are rising about about 2.5% a year.

    “The PCE is the best measure to look at,” Amemiya said. “It’s designed to capture the total cost of health care.”

    The PCE tries to take into account total health-care spending, including business contributions to employee health insurance as well as Medicaid and Medicare reimbursement rates.

    As of July, the core PCE was up at an annual rate of 4.2%, almost the same as core CPI.

    Whatever the case, the cost of health care and its impact on inflation still bear watching.

    The massive ups and downs in the CPI health-insurers index has even forced the Bureau of Labor Statistics to rejigger its once-a-year formula to try to be more timely and accurate.

    Whether it can truly capture the changes in medical costs is still an open question.

    “I don’t think there is an easy answer on this,” Stanley said.

    [ad_2]

    Source link

  • Pinoys back legalizing medical marijuana – Medical Marijuana Program Connection

    Pinoys back legalizing medical marijuana – Medical Marijuana Program Connection

    [ad_1]

    (UPDATE) THE legalization of marijuana for therapeutic purposes is being backed by majority of Filipinos, a recent study by independent think tank Capstone-Intel Corp. showed.

    The survey, conducted from August 1 to 10, found that 63 percent of the 1,205 respondents favored legalizing medical marijuana as long as its proponents “conduct more research [and] strict policy guidelines for access and dosage control.” The respondents also cited the need for more awareness and education on medical marijuana.

    The remaining 37 percent were against legalization.

    USDA Certified Organic Tinctures and salves
    Picture of cannabis plants taken at the Cannabis Expo Brazil, a hemp and cannabis industry exhibition, in Sao Paulo, Brazil, on September 15, 2023. (Photo by Nelson ALMEIDA / AFP)

    Picture of cannabis plants taken at the Cannabis Expo Brazil, a hemp and cannabis industry exhibition, in Sao Paulo, Brazil, on September 15, 2023. (Photo by Nelson ALMEIDA / AFP)

    The poll also found that 38 percent agreed that the legalization of medical marijuana could offer a viable solution for patients who have not found successful treatments through conventional medicine. On the other hand, 29 percent neither agreed nor disagreed with this statement, while 24 percent agreed that medical marijuana legalization could provide relief to such patients.

    The poll also showed that 49 percent of the respondents called for further research and reviews into the potential advantages and drawbacks of using cannabis for medical purposes.

    Get the latest news

    delivered to your inbox

    Sign up for The Manila Times newsletters

    By signing up with an email address, I acknowledge that I have read and agree to the Terms…

    Original Author Link click here to read complete story..

    [ad_2]

    MMP News Author

    Source link

  • Old North State Trust LLC Purchases 747 Shares of Laboratory Co. of America Holdings (NYSE:LH)

    Old North State Trust LLC Purchases 747 Shares of Laboratory Co. of America Holdings (NYSE:LH)

    [ad_1]

    Old North State Trust LLC grew its stake in shares of Laboratory Co. of America Holdings (NYSE:LH – Free Report) by 429.3% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 921 shares of the medical research company’s stock after buying an additional 747 shares during the quarter. Old North State Trust LLC’s holdings in Laboratory Co. of America were worth $40,000 at the end of the most recent quarter.

    Other institutional investors and hedge funds have also recently made changes to their positions in the company. WealthPLAN Partners LLC purchased a new stake in shares of Laboratory Co. of America during the 1st quarter valued at $25,000. Eagle Bay Advisors LLC purchased a new position in Laboratory Co. of America in the 2nd quarter worth $29,000. Zions Bancorporation N.A. raised its position in Laboratory Co. of America by 45.6% in the 4th quarter. Zions Bancorporation N.A. now owns 131 shares of the medical research company’s stock worth $31,000 after purchasing an additional 41 shares during the period. Compagnie Lombard Odier SCmA purchased a new position in Laboratory Co. of America in the 4th quarter worth $33,000. Finally, ST Germain D J Co. Inc. purchased a new position in Laboratory Co. of America in the 4th quarter worth $38,000. Hedge funds and other institutional investors own 89.37% of the company’s stock.

    Laboratory Co. of America Trading Down 1.0 %

    Shares of LH opened at $201.67 on Friday. The firm’s 50-day moving average price is $212.42 and its 200-day moving average price is $220.70. The firm has a market capitalization of $17.87 billion, a price-to-earnings ratio of 21.76 and a beta of 1.08. The company has a current ratio of 2.35, a quick ratio of 2.12 and a debt-to-equity ratio of 0.58. Laboratory Co. of America Holdings has a 1-year low of $166.93 and a 1-year high of $222.33.

    Laboratory Co. of America (NYSE:LH – Get Free Report) last announced its earnings results on Thursday, July 27th. The medical research company reported $3.42 earnings per share for the quarter, missing analysts’ consensus estimates of $3.47 by ($0.05). The company had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.77 billion. Laboratory Co. of America had a net margin of 5.89% and a return on equity of 14.62%. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same period in the previous year, the firm posted $4.96 EPS. Sell-side analysts anticipate that Laboratory Co. of America Holdings will post 13.68 EPS for the current year.

    Laboratory Co. of America Announces Dividend

    The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Tuesday, August 8th were paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.43%. The ex-dividend date of this dividend was Monday, August 7th. Laboratory Co. of America’s payout ratio is currently 31.07%.

    Analyst Upgrades and Downgrades

    A number of equities analysts recently commented on the stock. Wells Fargo & Company decreased their target price on shares of Laboratory Co. of America from $290.00 to $270.00 and set an “overweight” rating on the stock in a research report on Monday, August 14th. StockNews.com initiated coverage on shares of Laboratory Co. of America in a research report on Sunday, September 10th. They issued a “hold” rating on the stock. Mizuho reissued a “buy” rating and issued a $257.00 price target on shares of Laboratory Co. of America in a report on Friday. Credit Suisse Group cut their price target on shares of Laboratory Co. of America from $247.41 to $231.00 and set an “outperform” rating on the stock in a report on Wednesday, August 2nd. Finally, Morgan Stanley cut their price target on shares of Laboratory Co. of America from $285.00 to $260.00 and set an “overweight” rating on the stock in a report on Thursday, August 3rd. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $247.11.

    View Our Latest Analysis on LH

    Insider Buying and Selling

    In related news, Director Kerrii B. Anderson sold 5,000 shares of the business’s stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $211.57, for a total transaction of $1,057,850.00. Following the sale, the director now owns 15,275 shares of the company’s stock, valued at $3,231,731.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Laboratory Co. of America news, EVP Der Vaart Sandra D. Van sold 212 shares of Laboratory Co. of America stock in a transaction dated Thursday, June 29th. The shares were sold at an average price of $240.00, for a total value of $50,880.00. Following the completion of the transaction, the executive vice president now directly owns 7,605 shares of the company’s stock, valued at $1,825,200. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kerrii B. Anderson sold 5,000 shares of Laboratory Co. of America stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $211.57, for a total transaction of $1,057,850.00. Following the completion of the transaction, the director now directly owns 15,275 shares of the company’s stock, valued at $3,231,731.75. The disclosure for this sale can be found here. 0.65% of the stock is currently owned by insiders.

    Laboratory Co. of America Company Profile

    (Free Report)

    Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics and Labcorp Drug Development.

    Featured Articles

    Institutional Ownership by Quarter for Laboratory Co. of America (NYSE:LH)

    Receive News & Ratings for Laboratory Co. of America Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Laboratory Co. of America and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Viawealth LLC Purchases 126 Shares of UnitedHealth Group Incorporated (NYSE:UNH)

    Viawealth LLC Purchases 126 Shares of UnitedHealth Group Incorporated (NYSE:UNH)

    [ad_1]

    Viawealth LLC lifted its position in shares of UnitedHealth Group Incorporated (NYSE:UNH – Free Report) by 1.4% during the first quarter, Holdings Channel.com reports. The firm owned 9,201 shares of the healthcare conglomerate’s stock after acquiring an additional 126 shares during the period. UnitedHealth Group comprises 3.4% of Viawealth LLC’s investment portfolio, making the stock its 2nd biggest holding. Viawealth LLC’s holdings in UnitedHealth Group were worth $4,349,000 at the end of the most recent reporting period.

    A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Veritable L.P. grew its stake in shares of UnitedHealth Group by 2.8% during the 1st quarter. Veritable L.P. now owns 27,563 shares of the healthcare conglomerate’s stock worth $13,026,000 after purchasing an additional 748 shares during the period. Renaissance Technologies LLC lifted its position in shares of UnitedHealth Group by 169.4% during the 1st quarter. Renaissance Technologies LLC now owns 1,450,933 shares of the healthcare conglomerate’s stock valued at $685,697,000 after buying an additional 912,256 shares in the last quarter. Prospera Financial Services Inc lifted its position in shares of UnitedHealth Group by 17.3% during the 1st quarter. Prospera Financial Services Inc now owns 24,786 shares of the healthcare conglomerate’s stock valued at $11,719,000 after buying an additional 3,659 shares in the last quarter. Private Portfolio Partners LLC lifted its position in shares of UnitedHealth Group by 6.0% during the 1st quarter. Private Portfolio Partners LLC now owns 1,730 shares of the healthcare conglomerate’s stock valued at $818,000 after buying an additional 98 shares in the last quarter. Finally, Callan Family Office LLC lifted its position in shares of UnitedHealth Group by 125.5% during the 1st quarter. Callan Family Office LLC now owns 4,345 shares of the healthcare conglomerate’s stock valued at $2,053,000 after buying an additional 2,418 shares in the last quarter. Institutional investors and hedge funds own 85.69% of the company’s stock.

    UnitedHealth Group Stock Down 0.8 %

    Shares of NYSE:UNH opened at $480.77 on Friday. The business has a 50-day moving average price of $491.01 and a 200 day moving average price of $486.78. The company has a current ratio of 0.80, a quick ratio of 0.80 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $445.34 billion, a price-to-earnings ratio of 21.51, a PEG ratio of 1.40 and a beta of 0.66. UnitedHealth Group Incorporated has a 12-month low of $445.68 and a 12-month high of $558.10.

    UnitedHealth Group (NYSE:UNH – Get Free Report) last issued its quarterly earnings data on Friday, July 14th. The healthcare conglomerate reported $6.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.92 by $0.22. The firm had revenue of $92.90 billion during the quarter, compared to the consensus estimate of $90.97 billion. UnitedHealth Group had a return on equity of 26.72% and a net margin of 6.06%. The company’s quarterly revenue was up 15.6% on a year-over-year basis. During the same period last year, the company earned $5.57 EPS. Sell-side analysts expect that UnitedHealth Group Incorporated will post 24.83 EPS for the current year.

    UnitedHealth Group Dividend Announcement

    The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 19th. Stockholders of record on Monday, September 11th will be paid a $1.88 dividend. This represents a $7.52 annualized dividend and a dividend yield of 1.56%. The ex-dividend date is Friday, September 8th. UnitedHealth Group’s payout ratio is presently 33.65%.

    Wall Street Analysts Forecast Growth

    UNH has been the topic of a number of research reports. SVB Securities decreased their price objective on UnitedHealth Group from $625.00 to $560.00 in a report on Wednesday, June 14th. Morgan Stanley restated an “overweight” rating and issued a $587.00 price objective on shares of UnitedHealth Group in a report on Friday, July 14th. StockNews.com initiated coverage on UnitedHealth Group in a report on Thursday, August 17th. They issued a “buy” rating on the stock. Piper Sandler initiated coverage on UnitedHealth Group in a report on Thursday, May 25th. They issued an “overweight” rating and a $580.00 price objective on the stock. Finally, Sanford C. Bernstein upgraded UnitedHealth Group from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $595.00 to $603.00 in a report on Tuesday, July 18th. Two equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $575.65.

    Read Our Latest Research Report on UNH

    Insider Activity

    In related news, CEO Andrew Witty sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 19th. The stock was sold at an average price of $506.19, for a total value of $2,024,760.00. Following the completion of the transaction, the chief executive officer now directly owns 78,573 shares of the company’s stock, valued at $39,772,866.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.35% of the company’s stock.

    About UnitedHealth Group

    (Free Report)

    UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children’s health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.

    Featured Stories

    Want to see what other hedge funds are holding UNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UnitedHealth Group Incorporated (NYSE:UNH – Free Report).

    Institutional Ownership by Quarter for UnitedHealth Group (NYSE:UNH)

    Receive News & Ratings for UnitedHealth Group Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for UnitedHealth Group and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • 7 Minutes Of Payday 3

    7 Minutes Of Payday 3

    [ad_1]

    Read more…

    [ad_2]

    Eric Schulkin

    Source link

  • Analyzing Medical Marijuana (MJNA) and Its Rivals – Medical Marijuana Program Connection

    Analyzing Medical Marijuana (MJNA) and Its Rivals – Medical Marijuana Program Connection

    [ad_1]

    Medical Marijuana (OTCMKTS:MJNA – Get Free Report) is one of 258 public companies in the “Drug Manufacturers—Specialty & Generic” industry, but how does it compare to its peers? We will compare Medical Marijuana to similar companies based on the strength of its institutional ownership, profitability, valuation, dividends, analyst recommendations, earnings and risk.

    Profitability

    This table compares Medical Marijuana and its peers’ net margins, return on equity and return on assets.

    Net Margins Return on Equity Return on Assets
    Medical Marijuana N/A N/A N/A
    Medical Marijuana Competitors -86.05% -59.51% -13.31%

    Valuation and Earnings

    This table compares Medical Marijuana and its peers top-line revenue, earnings per share (EPS) and valuation.

    Gross Revenue Net Income Price/Earnings Ratio
    Medical Marijuana N/A N/A -0.59
    Medical Marijuana Competitors $3.53 billion -$46.51 million 117.90
    Want More Great Investing Ideas?

    USDA Certified Organic Tinctures and salves

    Medical Marijuana’s peers have higher revenue, but lower earnings than Medical Marijuana. Medical Marijuana is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

    Insider and Institutional Ownership

    0.0% of Medical Marijuana shares are owned by institutional investors. Comparatively, 25.1% of shares of all “Drug Manufacturers—Specialty & Generic” companies are owned by institutional investors. 26.2% of shares of all…

    Original Author Link click here to read complete story..

    [ad_2]

    MMP News Author

    Source link

  • 6,561 Shares in Bio-Techne Co. (NASDAQ:TECH) Bought by Private Advisor Group LLC

    6,561 Shares in Bio-Techne Co. (NASDAQ:TECH) Bought by Private Advisor Group LLC

    [ad_1]

    Private Advisor Group LLC acquired a new position in shares of Bio-Techne Co. (NASDAQ:TECH – Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 6,561 shares of the biotechnology company’s stock, valued at approximately $487,000.

    Several other hedge funds have also added to or reduced their stakes in the business. Zions Bancorporation N.A. raised its stake in Bio-Techne by 0.6% during the 1st quarter. Zions Bancorporation N.A. now owns 22,222 shares of the biotechnology company’s stock worth $1,649,000 after buying an additional 129 shares during the period. Credit Suisse AG raised its stake in Bio-Techne by 3.5% during the 1st quarter. Credit Suisse AG now owns 271,674 shares of the biotechnology company’s stock worth $20,155,000 after buying an additional 9,160 shares during the period. LPL Financial LLC raised its stake in Bio-Techne by 15.8% during the 1st quarter. LPL Financial LLC now owns 36,719 shares of the biotechnology company’s stock worth $2,724,000 after buying an additional 5,018 shares during the period. iSAM Funds UK Ltd acquired a new stake in Bio-Techne during the 1st quarter worth $225,000. Finally, Kentucky Retirement Systems Insurance Trust Fund acquired a new stake in shares of Bio-Techne in the 1st quarter valued at about $415,000. Institutional investors and hedge funds own 94.64% of the company’s stock.

    Insiders Place Their Bets

    In other Bio-Techne news, CEO Charles R. Kummeth sold 80,000 shares of the business’s stock in a transaction that occurred on Friday, July 21st. The stock was sold at an average price of $88.36, for a total transaction of $7,068,800.00. Following the transaction, the chief executive officer now owns 1,258,766 shares of the company’s stock, valued at $111,224,563.76. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, CEO Charles R. Kummeth sold 80,000 shares of the company’s stock in a transaction that occurred on Friday, July 21st. The stock was sold at an average price of $88.36, for a total value of $7,068,800.00. Following the transaction, the chief executive officer now owns 1,258,766 shares of the company’s stock, valued at $111,224,563.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Roeland Nusse sold 8,939 shares of the company’s stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $80.32, for a total value of $717,980.48. Following the completion of the transaction, the director now directly owns 51,872 shares in the company, valued at approximately $4,166,359.04. The disclosure for this sale can be found here. Company insiders own 4.45% of the company’s stock.

    Bio-Techne Price Performance

    NASDAQ:TECH opened at $78.76 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 3.50 and a current ratio of 4.84. The stock’s 50-day simple moving average is $81.87 and its 200 day simple moving average is $79.47. The company has a market cap of $12.46 billion, a P/E ratio of 44.75, a P/E/G ratio of 4.13 and a beta of 1.22. Bio-Techne Co. has a 52-week low of $68.00 and a 52-week high of $90.63.

    Bio-Techne (NASDAQ:TECH – Get Free Report) last released its earnings results on Tuesday, August 8th. The biotechnology company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.07. The business had revenue of $301.32 million for the quarter, compared to the consensus estimate of $304.71 million. Bio-Techne had a return on equity of 15.47% and a net margin of 25.10%. As a group, sell-side analysts forecast that Bio-Techne Co. will post 1.81 EPS for the current fiscal year.

    Bio-Techne Dividend Announcement

    The firm also recently declared a quarterly dividend, which was paid on Friday, September 1st. Shareholders of record on Friday, August 18th were given a dividend of $0.08 per share. This represents a $0.32 dividend on an annualized basis and a yield of 0.41%. The ex-dividend date was Thursday, August 17th. Bio-Techne’s dividend payout ratio (DPR) is presently 18.18%.

    Wall Street Analysts Forecast Growth

    TECH has been the topic of a number of research reports. William Blair initiated coverage on Bio-Techne in a report on Monday, August 28th. They issued an “outperform” rating on the stock. Stephens restated an “overweight” rating and issued a $100.00 price target on shares of Bio-Techne in a report on Wednesday, August 9th. Robert W. Baird cut their price target on Bio-Techne from $100.00 to $90.00 in a report on Wednesday, August 9th. Benchmark restated a “buy” rating and issued a $120.00 price target on shares of Bio-Techne in a report on Friday, August 18th. Finally, StockNews.com upgraded Bio-Techne from a “hold” rating to a “buy” rating in a report on Friday, August 25th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $101.78.

    Read Our Latest Research Report on TECH

    About Bio-Techne

    (Free Report)

    Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.

    Featured Articles

    Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Techne Co. (NASDAQ:TECH – Free Report).

    Institutional Ownership by Quarter for Bio-Techne (NASDAQ:TECH)

    Receive News & Ratings for Bio-Techne Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bio-Techne and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Pacific Founders Ugp I. Chicago Buys 90,000 Shares of P3 Health Partners Inc. (NASDAQ:PIII) Stock

    Pacific Founders Ugp I. Chicago Buys 90,000 Shares of P3 Health Partners Inc. (NASDAQ:PIII) Stock

    [ad_1]

    P3 Health Partners Inc. (NASDAQ:PIII – Get Free Report) major shareholder Pacific Founders Ugp I. Chicago bought 90,000 shares of P3 Health Partners stock in a transaction that occurred on Wednesday, August 30th. The shares were acquired at an average cost of $1.83 per share, for a total transaction of $164,700.00. Following the acquisition, the insider now owns 49,305,442 shares in the company, valued at approximately $90,228,958.86. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

    P3 Health Partners Trading Up 0.5 %

    Shares of PIII opened at $1.98 on Friday. The stock has a market capitalization of $619.10 million, a P/E ratio of 0.00 and a beta of 1.23. The company has a quick ratio of 0.69, a current ratio of 0.69 and a debt-to-equity ratio of 16.13. The firm has a fifty day simple moving average of $2.32 and a two-hundred day simple moving average of $2.16. P3 Health Partners Inc. has a twelve month low of $0.70 and a twelve month high of $7.05.

    P3 Health Partners (NASDAQ:PIII – Get Free Report) last announced its quarterly earnings results on Monday, August 7th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.15. P3 Health Partners had a negative net margin of 10.92% and a negative return on equity of 2,471.27%. The business had revenue of $329.09 million during the quarter, compared to analysts’ expectations of $303.30 million. On average, research analysts anticipate that P3 Health Partners Inc. will post -0.96 EPS for the current year.

    Wall Street Analyst Weigh In

    Several equities analysts recently commented on the stock. BTIG Research initiated coverage on shares of P3 Health Partners in a report on Thursday. They set a “buy” rating on the stock. TD Cowen initiated coverage on shares of P3 Health Partners in a research report on Friday, June 30th. They set a “market perform” rating for the company.

    View Our Latest Stock Report on P3 Health Partners

    Institutional Inflows and Outflows

    Large investors have recently bought and sold shares of the business. Marietta Investment Partners LLC bought a new stake in P3 Health Partners during the 1st quarter valued at about $26,000. Squarepoint Ops LLC bought a new stake in P3 Health Partners during the 4th quarter valued at about $31,000. Walleye Trading LLC bought a new stake in P3 Health Partners during the 2nd quarter valued at about $34,000. State Board of Administration of Florida Retirement System bought a new stake in P3 Health Partners during the 2nd quarter valued at about $34,000. Finally, SlateStone Wealth LLC bought a new stake in P3 Health Partners during the 2nd quarter valued at about $39,000. 23.57% of the stock is owned by hedge funds and other institutional investors.

    P3 Health Partners Company Profile

    (Get Free Report)

    P3 Health Partners Inc, a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. The company is based in Henderson, Nevada.

    Featured Stories

    Insider Buying and Selling by Quarter for P3 Health Partners (NASDAQ:PIII)

    Receive News & Ratings for P3 Health Partners Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for P3 Health Partners and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • U.S. Announces First 10 Drugs For Medicare Price Negotiation

    U.S. Announces First 10 Drugs For Medicare Price Negotiation

    [ad_1]

    The Biden administration released its list of the first 10 drugs that Medicare will negotiate for price cuts with drugmakers, including some of the most widely prescribed or expensive drugs for conditions such as heart disease, diabetes, and autoimmune conditions. What do you think?

    “My brand of cigarettes better be on that list.”

    Horace Steinberg, Unemployed

    Archaeologists Uncover Living Guy By Mistake

    “It’s exciting to see America edge closer to ‘developed nation’ status.”

    Elyssa Moore, Knee Model

    “This will only encourage more people to develop atrial fibrillation.”

    Dinesh Rao, Hydration Supervisor

    [ad_2]

    Source link

  • Holocaust Deniers Explain Why They Deny The Holocaust

    Holocaust Deniers Explain Why They Deny The Holocaust

    [ad_1]

    Read more…

    [ad_2]

    Source link

  • DeSantis Bans AP Psychology Out Of Fear People Will Figure Out What’s Wrong With Him

    DeSantis Bans AP Psychology Out Of Fear People Will Figure Out What’s Wrong With Him

    [ad_1]

    TALLAHASSEE, FL—Explaining that the course would teach thousands of high schoolers harmful information about identifying psychological disorders, Florida Gov. Ron DeSantis announced Friday that the state would ban AP Psychology out of fear that people might figure out what precisely is wrong with him. “If students come to understand ideas, theories, and terminology associated with mental disorders like, say, narcissistic personality disorder, it could get them that much closer to understanding why exactly I behave the way I do,” said DeSantis, adding that such Advanced Placement classes would only indoctrinate the state’s students into recognizing the many mental health issues that manifest in his behavior on a daily basis. “These courses will make teens look critically at why I act so strangely in seemingly normal human situations and, frankly, allow them to work out that something in my brain is probably abnormal. Floridians know that should never happen. If I don’t know why I seem to be in pain every time I smile, our high school students certainly shouldn’t.” DeSantis went on to announce that he would also be banning couples counseling in the state after advisors suggested his wife Casey DeSantis might use the dangerous practice against him some day.

    Ron DeSantis Introduces New Son Barron Trump

    [ad_2]

    Source link

  • Advisors Capital Management LLC Boosts Stock Position in Amgen Inc. (NASDAQ:AMGN)

    Advisors Capital Management LLC Boosts Stock Position in Amgen Inc. (NASDAQ:AMGN)

    [ad_1]

    Advisors Capital Management LLC lifted its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 24.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,732 shares of the medical research company’s stock after purchasing an additional 534 shares during the period. Advisors Capital Management LLC’s holdings in Amgen were worth $661,000 as of its most recent SEC filing.

    Other institutional investors also recently modified their holdings of the company. Tanglewood Legacy Advisors LLC purchased a new stake in shares of Amgen during the fourth quarter worth about $26,000. Ruedi Wealth Management Inc. purchased a new stake in shares of Amgen during the fourth quarter worth about $27,000. GW&K Investment Management LLC lifted its holdings in Amgen by 200.0% in the fourth quarter. GW&K Investment Management LLC now owns 120 shares of the medical research company’s stock worth $32,000 after buying an additional 80 shares during the period. AXS Investments LLC purchased a new stake in Amgen in the fourth quarter worth about $33,000. Finally, General Partner Inc. bought a new stake in shares of Amgen during the first quarter valued at approximately $32,000. 74.70% of the stock is currently owned by hedge funds and other institutional investors.

    Amgen Trading Down 0.7 %

    Shares of Amgen stock opened at $230.41 on Thursday. The company has a market capitalization of $123.11 billion, a P/E ratio of 15.66, a P/E/G ratio of 1.91 and a beta of 0.63. The company has a debt-to-equity ratio of 11.36, a quick ratio of 2.79 and a current ratio of 3.14. The company has a fifty day moving average of $225.66 and a 200 day moving average of $235.47. Amgen Inc. has a fifty-two week low of $211.71 and a fifty-two week high of $296.67.

    Amgen Dividend Announcement

    The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Friday, August 18th will be given a $2.13 dividend. This represents a $8.52 dividend on an annualized basis and a yield of 3.70%. Amgen’s dividend payout ratio (DPR) is currently 57.92%.

    Wall Street Analyst Weigh In

    Several brokerages recently weighed in on AMGN. Barclays reduced their price target on shares of Amgen from $225.00 to $210.00 in a research report on Tuesday, July 11th. Mizuho lifted their target price on shares of Amgen from $208.00 to $214.00 in a research report on Wednesday, May 3rd. Piper Sandler cut their target price on shares of Amgen from $293.00 to $288.00 in a research report on Friday, April 28th. Jefferies Financial Group cut their target price on shares of Amgen from $325.00 to $275.00 in a research report on Friday, July 7th. Finally, Credit Suisse Group cut their target price on shares of Amgen from $220.00 to $200.00 in a research report on Wednesday, July 12th. Four equities research analysts have rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $249.12.

    Get Our Latest Stock Analysis on Amgen

    Amgen Company Profile

    (Free Report)

    Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

    See Also

    Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

    Receive News & Ratings for Amgen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amgen and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Tornado Destroys Pfizer Plant In North Carolina

    Tornado Destroys Pfizer Plant In North Carolina

    [ad_1]

    A tornado in North Carolina ripped through a Pfizer pharmaceutical facility that produces nearly 25% of all sterile injectable medicines used in U.S. hospitals, sparking concerns about worsening drug shortages. What do you think?

    “I hope this doesn’t prevent me from being able to afford the drugs I can’t afford.”

    Sienna Kern, Preservationist

    This Week’s Most Viral News: July 21, 2023

    “I found a syringe on the sidewalk if that helps?”

    Brad Dickerson, Unemployed

    “Never thought I’d have to connect the dots between climate change and my Viagra supply.”

    Lance Jakobsen, Marine Firefighter

    [ad_2]

    Source link

  • Cwm LLC Raises Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

    Cwm LLC Raises Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

    [ad_1]

    Cwm LLC increased its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG – Free Report) by 23.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,012 shares of the medical equipment provider’s stock after purchasing an additional 2,298 shares during the quarter. Cwm LLC’s holdings in Intuitive Surgical were worth $3,069,000 as of its most recent SEC filing.

    A number of other hedge funds have also recently made changes to their positions in the stock. Azimuth Capital Investment Management LLC increased its position in Intuitive Surgical by 48.4% during the 4th quarter. Azimuth Capital Investment Management LLC now owns 54,074 shares of the medical equipment provider’s stock valued at $14,349,000 after buying an additional 17,633 shares in the last quarter. Ferguson Wellman Capital Management Inc. acquired a new position in Intuitive Surgical during the 4th quarter valued at about $259,000. Mn Services Vermogensbeheer B.V. increased its position in Intuitive Surgical by 3.7% during the 1st quarter. Mn Services Vermogensbeheer B.V. now owns 178,500 shares of the medical equipment provider’s stock valued at $45,601,000 after buying an additional 6,400 shares in the last quarter. Concord Wealth Partners increased its holdings in shares of Intuitive Surgical by 32.2% in the first quarter. Concord Wealth Partners now owns 530 shares of the medical equipment provider’s stock valued at $135,000 after purchasing an additional 129 shares during the period. Finally, First National Bank of Omaha acquired a new position in shares of Intuitive Surgical in the fourth quarter valued at about $205,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

    Wall Street Analysts Forecast Growth

    A number of brokerages have issued reports on ISRG. Morgan Stanley increased their price target on Intuitive Surgical from $265.00 to $285.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 19th. Royal Bank of Canada raised their target price on Intuitive Surgical from $309.00 to $355.00 in a research report on Wednesday, July 12th. Evercore ISI raised their target price on Intuitive Surgical from $240.00 to $270.00 and gave the company an “inline” rating in a research report on Wednesday, April 19th. JPMorgan Chase & Co. increased their price target on Intuitive Surgical from $250.00 to $335.00 and gave the company an “overweight” rating in a report on Wednesday, April 19th. Finally, Sanford C. Bernstein raised their target price on Intuitive Surgical from $350.00 to $365.00 in a research note on Wednesday, May 31st. Five investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, Intuitive Surgical presently has an average rating of “Moderate Buy” and a consensus price target of $323.48.

    Intuitive Surgical Price Performance

    Shares of NASDAQ ISRG opened at $347.66 on Friday. The company has a market capitalization of $121.82 billion, a price-to-earnings ratio of 94.99, a price-to-earnings-growth ratio of 6.33 and a beta of 1.32. Intuitive Surgical, Inc. has a 1 year low of $180.07 and a 1 year high of $358.07. The business has a 50-day moving average of $324.13 and a two-hundred day moving average of $281.19.

    Intuitive Surgical (NASDAQ:ISRG – Get Free Report) last issued its quarterly earnings results on Thursday, July 20th. The medical equipment provider reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.33 by $0.09. The firm had revenue of $1.76 billion for the quarter, compared to analysts’ expectations of $1.74 billion. Intuitive Surgical had a return on equity of 11.39% and a net margin of 20.40%. The firm’s revenue for the quarter was up 15.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.85 EPS. As a group, equities research analysts expect that Intuitive Surgical, Inc. will post 4.31 earnings per share for the current year.

    Insiders Place Their Bets

    In other Intuitive Surgical news, VP Marshall Mohr sold 11,250 shares of the business’s stock in a transaction that occurred on Wednesday, June 14th. The stock was sold at an average price of $325.00, for a total transaction of $3,656,250.00. Following the transaction, the vice president now owns 24,136 shares in the company, valued at approximately $7,844,200. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, EVP David J. Rosa sold 40,764 shares of the company’s stock in a transaction that occurred on Monday, April 24th. The stock was sold at an average price of $299.20, for a total value of $12,196,588.80. Following the sale, the executive vice president now owns 155,712 shares in the company, valued at approximately $46,589,030.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Marshall Mohr sold 11,250 shares of the company’s stock in a transaction that occurred on Wednesday, June 14th. The stock was sold at an average price of $325.00, for a total value of $3,656,250.00. Following the completion of the sale, the vice president now owns 24,136 shares in the company, valued at approximately $7,844,200. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 63,347 shares of company stock worth $19,349,510. Company insiders own 0.90% of the company’s stock.

    Intuitive Surgical Profile

    (Free Report)

    Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

    See Also

    Want to see what other hedge funds are holding ISRG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intuitive Surgical, Inc. (NASDAQ:ISRG – Free Report).

    Institutional Ownership by Quarter for Intuitive Surgical (NASDAQ:ISRG)

    Receive News & Ratings for Intuitive Surgical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Intuitive Surgical and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Theseus Pharmaceuticals (NASDAQ:THRX) PT Lowered to $7.00

    Theseus Pharmaceuticals (NASDAQ:THRX) PT Lowered to $7.00

    [ad_1]

    Theseus Pharmaceuticals (NASDAQ:THRX – Get Free Report) had its target price cut by analysts at Wedbush from $24.00 to $7.00 in a research report issued to clients and investors on Friday, MarketBeat reports. The firm currently has an “outperform” rating on the stock. Wedbush’s price objective would indicate a potential upside of 163.16% from the company’s current price.

    A number of other analysts have also recently weighed in on the stock. HC Wainwright decreased their price target on shares of Theseus Pharmaceuticals from $22.00 to $9.00 and set a “buy” rating for the company in a research report on Friday. Needham & Company LLC downgraded Theseus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Theseus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

    Theseus Pharmaceuticals Price Performance

    Theseus Pharmaceuticals stock opened at $2.66 on Friday. The company has a market cap of $115.91 million, a price-to-earnings ratio of -1.94 and a beta of 4.03. Theseus Pharmaceuticals has a 12 month low of $2.62 and a 12 month high of $14.77. The stock’s 50-day moving average is $9.46 and its 200-day moving average is $9.64.

    Theseus Pharmaceuticals (NASDAQ:THRX – Get Free Report) last posted its quarterly earnings results on Thursday, May 11th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.08. Research analysts anticipate that Theseus Pharmaceuticals will post -1.58 EPS for the current year.

    Hedge Funds Weigh In On Theseus Pharmaceuticals

    A number of institutional investors and hedge funds have recently added to or reduced their stakes in THRX. Tower Research Capital LLC TRC increased its stake in shares of Theseus Pharmaceuticals by 66.0% in the third quarter. Tower Research Capital LLC TRC now owns 4,420 shares of the company’s stock worth $26,000 after buying an additional 1,757 shares during the last quarter. Barclays PLC increased its position in shares of Theseus Pharmaceuticals by 76.0% in the 4th quarter. Barclays PLC now owns 8,904 shares of the company’s stock worth $44,000 after purchasing an additional 3,844 shares during the last quarter. American International Group Inc. raised its stake in shares of Theseus Pharmaceuticals by 39.2% in the 2nd quarter. American International Group Inc. now owns 7,952 shares of the company’s stock valued at $44,000 after purchasing an additional 2,238 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Theseus Pharmaceuticals by 68.3% during the second quarter. JPMorgan Chase & Co. now owns 9,084 shares of the company’s stock worth $50,000 after purchasing an additional 3,687 shares during the last quarter. Finally, Morgan Stanley grew its stake in Theseus Pharmaceuticals by 31.1% in the fourth quarter. Morgan Stanley now owns 11,478 shares of the company’s stock worth $57,000 after purchasing an additional 2,721 shares in the last quarter. 95.84% of the stock is owned by hedge funds and other institutional investors.

    Theseus Pharmaceuticals Company Profile

    (Get Free Report)

    Theseus Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer.

    Featured Stories

    Analyst Recommendations for Theseus Pharmaceuticals (NASDAQ:THRX)

    Receive News & Ratings for Theseus Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Theseus Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Investors Purchase High Volume of Iovance Biotherapeutics Call Options (NASDAQ:IOVA)

    Investors Purchase High Volume of Iovance Biotherapeutics Call Options (NASDAQ:IOVA)

    [ad_1]

    Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) saw some unusual options trading on Thursday. Investors acquired 3,690 call options on the stock. This represents an increase of 52% compared to the typical volume of 2,435 call options.

    Iovance Biotherapeutics Price Performance

    Shares of IOVA stock opened at $7.76 on Friday. The company has a fifty day moving average price of $7.87 and a two-hundred day moving average price of $7.03. The stock has a market cap of $1.74 billion, a P/E ratio of -3.23 and a beta of 0.11. Iovance Biotherapeutics has a one year low of $5.28 and a one year high of $13.44.

    Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) last released its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.34. During the same quarter in the prior year, the business earned ($0.58) earnings per share. As a group, equities research analysts anticipate that Iovance Biotherapeutics will post -2.4 EPS for the current fiscal year.

    Institutional Investors Weigh In On Iovance Biotherapeutics

    A number of institutional investors have recently modified their holdings of IOVA. Assetmark Inc. increased its stake in shares of Iovance Biotherapeutics by 299.5% in the first quarter. Assetmark Inc. now owns 4,223 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 3,166 shares in the last quarter. US Bancorp DE raised its stake in shares of Iovance Biotherapeutics by 72.7% during the first quarter. US Bancorp DE now owns 5,591 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 2,354 shares in the last quarter. Royal Bank of Canada increased its stake in shares of Iovance Biotherapeutics by 54.5% in the third quarter. Royal Bank of Canada now owns 5,066 shares of the biotechnology company’s stock worth $48,000 after buying an additional 1,787 shares during the period. Systematic Financial Management LP bought a new stake in shares of Iovance Biotherapeutics during the 1st quarter valued at $48,000. Finally, Lazard Asset Management LLC boosted its stake in Iovance Biotherapeutics by 38.5% in the 1st quarter. Lazard Asset Management LLC now owns 3,357 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 934 shares in the last quarter. 89.80% of the stock is owned by institutional investors.

    Wall Street Analysts Forecast Growth

    A number of brokerages have issued reports on IOVA. Wells Fargo & Company raised shares of Iovance Biotherapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $11.00 to $17.00 in a report on Tuesday, May 30th. Robert W. Baird boosted their price target on shares of Iovance Biotherapeutics from $20.00 to $23.00 in a report on Tuesday, May 23rd. Stifel Nicolaus boosted their target price on shares of Iovance Biotherapeutics from $21.00 to $24.00 in a research report on Tuesday, May 30th. Finally, StockNews.com upgraded shares of Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a report on Sunday, July 9th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $19.09.

    Iovance Biotherapeutics Company Profile

    (Get Free Report)

    Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient’s immune system to eradicate cancer cells. The company’s lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer.

    Recommended Stories

    Receive News & Ratings for Iovance Biotherapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Iovance Biotherapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Chuck Schumer Calls On FDA To Investigate 72-Hour Erection He Got From Prime Energy Drink

    Chuck Schumer Calls On FDA To Investigate 72-Hour Erection He Got From Prime Energy Drink

    [ad_1]

    WASHINGTON—Calling the influencer-backed beverage a serious public health concern, a visibly erect Sen. Chuck Schumer (D-NY) called on the FDA Monday to investigate the 72-hour erection he had experienced as a result of drinking Logan Paul’s Prime energy drink. “Buyers and parents need to understand the risks involved with having a three-day stiffy that’s as hard as a mallet,” said the Senate Minority Leader, who winced as he pulled at his pants from behind the podium, confirming that his erection remained unchanged despite repeated efforts to take a cold shower, masturbate, and make love to his wife, Iris. “After drinking just one can of this stuff last week, I still feel the effects of arousal, to the point that I cannot physically urinate without leaning over the toilet. It’s just throbbing down there, and I’m worried it’s here for good. Durbin took a sip, too, and look at him—he can’t even sit down. This beverage, marketed simply as a ‘hydration supplement’ has no business being on U.S. shelves. I am begging the FDA: Please, for the love of God, investigate my penis.” At press time, Schumer was overheard explaining to the Senate Ethics Committee that his bulging erection was not sexual, but rather a physiological response to blue raspberry flavoring.

    This Week’s Most Viral News: June 30, 2023

    [ad_2]

    Source link